Nature Communications (Apr 2019)
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
- Peng Liu,
- Liwei Zhao,
- Jonathan Pol,
- Sarah Levesque,
- Adriana Petrazzuolo,
- Christina Pfirschke,
- Camilla Engblom,
- Steffen Rickelt,
- Takahiro Yamazaki,
- Kristina Iribarren,
- Laura Senovilla,
- Lucillia Bezu,
- Erika Vacchelli,
- Valentina Sica,
- Andréa Melis,
- Tiffany Martin,
- Lin Xia,
- Heng Yang,
- Qingqing Li,
- Jinfeng Chen,
- Sylvère Durand,
- Fanny Aprahamian,
- Deborah Lefevre,
- Sophie Broutin,
- Angelo Paci,
- Amaury Bongers,
- Veronique Minard-Colin,
- Eric Tartour,
- Laurence Zitvogel,
- Lionel Apetoh,
- Yuting Ma,
- Mikael J. Pittet,
- Oliver Kepp,
- Guido Kroemer
Affiliations
- Peng Liu
- Faculty of Medicine, University of Paris Sud
- Liwei Zhao
- Faculty of Medicine, University of Paris Sud
- Jonathan Pol
- Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus
- Sarah Levesque
- Faculty of Medicine, University of Paris Sud
- Adriana Petrazzuolo
- Faculty of Medicine, University of Paris Sud
- Christina Pfirschke
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School
- Camilla Engblom
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School
- Steffen Rickelt
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Takahiro Yamazaki
- Department of Radiation Oncology, Weill Cornell Medical College
- Kristina Iribarren
- Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus
- Laura Senovilla
- Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus
- Lucillia Bezu
- Faculty of Medicine, University of Paris Sud
- Erika Vacchelli
- Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus
- Valentina Sica
- Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus
- Andréa Melis
- Centre de Recherche INSERM LNC-
- Tiffany Martin
- Centre de Recherche INSERM LNC-
- Lin Xia
- Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College
- Heng Yang
- Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College
- Qingqing Li
- Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College
- Jinfeng Chen
- Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College
- Sylvère Durand
- Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus
- Fanny Aprahamian
- Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus
- Deborah Lefevre
- Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus
- Sophie Broutin
- Department of Pharmacology, Institut Gustave Roussy
- Angelo Paci
- Department of Pharmacology, Institut Gustave Roussy
- Amaury Bongers
- Department of Pharmacology, Institut Gustave Roussy
- Veronique Minard-Colin
- Institut de Cancérologie, Gustave Roussy Cancer Campus (GRCC)
- Eric Tartour
- INSERM U970, Université Paris Descartes Sorbonne Paris-Cité
- Laurence Zitvogel
- Faculty of Medicine, University of Paris Sud
- Lionel Apetoh
- Centre de Recherche INSERM LNC-
- Yuting Ma
- Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College
- Mikael J. Pittet
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School
- Oliver Kepp
- Faculty of Medicine, University of Paris Sud
- Guido Kroemer
- Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus
- DOI
- https://doi.org/10.1038/s41467-019-09415-3
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 17
Abstract
Certain chemotherapeutic agents can exert their anticancer effect through indirect immune-dependent mechanism. Here, the authors screen a library of tyrosine kinase inhibitors and show that crizotinib is an effective stimulator of immunogenic cell death and can potentiate the efficacy of immune checkpoint blockade.
